Understanding drug ototoxicity: Molecular insights for prevention and clinical management

Expert Opinion on Drug Safety

Volumn 5, Issue 3, 2006, Pages 383-399

  Yorgason, Joshua G ^a   Fayad, Jose N ^b   Kalinec, Federico ^a  

^a HOUSE EAR INSTITUTE   (United States)

^b Eccles Temporal Bone Histopathology Laboratory   (United States)

Author keywords

Aminoglycoside; Auditory system; Drug Ototoxicity; Hair cells; Inner ear; Vestibular system

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARNITINE; CLARITHROMYCIN; DIHYDROSTREPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; KANAMYCIN; LEUPEPTIN; LOOP DIURETIC AGENT; METICILLIN; MITOCHONDRIAL DNA; NEOMYCIN; NETILMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; PROTEIN BCL 2; QUININE; QUINOLONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; STREPTOMYCIN; STRESS ACTIVATED PROTEIN KINASE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AUDIOMETRY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BALANCE DISORDER; BLINDNESS; CLINICAL TRIAL; COCHLEA PROSTHESIS; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG UPTAKE; DYSPHORIA; EAR SURGERY; EARDRUM PERFORATION; ELECTROSTIMULATION THERAPY; EXTERNAL OTITIS; EYE INFECTION; FETOTOXICITY; GENE MUTATION; HEADACHE; HEARING AID; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; LUNG EDEMA; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PERMISSIBLE DOSE; MENIERE DISEASE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NYSTAGMUS; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; REVIEW; RISK BENEFIT ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPPURATIVE OTITIS MEDIA; SYSTEMATIC REVIEW; TINNITUS; TUBERCULOSIS; VERTIGO;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EAR, INNER; HEARING LOSS; HUMANS;

EID: 33646556098     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.3.383     Document Type: Review

References (225)

1. FORGE A, SCHACHT J: Aminoglycoside antibiotics. Audiol. Neuro-Otol. (2000) 5:3-22.
2. KONDO S, HOTTA K. Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications. J. Infect. Chemother. (1999) 5(1):1-9.
3. DAVIS BD: Mechanism of bactericidal action of aminoglycosides. Microbiol. Rev. (1987) 51(3):341-350.
4. GOVAERTS PJ, CLAES J, VAN DE HEYNING PH et al: Aminoglycoside-induced ototoxicity. Toxicol. Lett. (1990) 52(3):227-251.
5. SCHATZ A, BUGIE E, WAKSMAN SA. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. 1944. Clin. Orthop. Relat. Res. (2005) 437:3-6.
6. SCHUKNECHT HF: Disorders of intoxication. In: Pathology of the Ear, Bussy KR (Ed.) Lea and Febiger, Philadelphia (1993):255-277.
7. UMEZAWA H, UEDA M, MAEDA K et al: Production and isolation of a new antibiotic: kanamycin. J. Antibiot. (Tokyo) (1957) 10(5):181-188.
8. BREWER NS: Antimicrobial agents-Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. Mayo Clin. Proc. (1977) 52(11):675-679.
9. LERNER SA, MATZ GJ: Aminoglycoside ototoxicity, Am. J. Otolaryngol (1980) 1(2):169-179.
10. CHAMBERS HF, SANDE MA: The aminoglycosides. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Hardman JG et al. (Eds) McGraw-Hill, New York (1996):1103-1121.
11. MATZ GJ, RYBAK LP: Ototoxic Drugs. In: Head and Neck Surgery - Otolaryngology, Byron J et al. (Eds) Lippincott Company, Philadelphia (1993):1793-1802.
12. Black FO, GIANNA-POULIN C, PESZNECKER SC: Recovery from vestibular ototoxicity. Otol. Neurotol. (2001) 22(5):662-671.
13. LIGHT JP, SILVERSTEIN H, JACKSON LE: Gentamicin perfusion vestibular response and hearing loss. Otol. Neurotol. (2003) 24(2):294-298.
14. COHEN-KEREM R, KISILEVSKY V, EINARSON TR et al.: Intratympanic gentamicin for Meniere's disease: a meta-analysis. Laryngoscope (2004) 114(12):2085-2091.
15. BERRYHILL WE, GRAHAM MD: Chemical and physical labyrinthectomy for Meniere's disease. Otolaryngol. Clin. North Am. (2002) 35(3):675-682.
16. BRZEZINSKA M, BENVENISTE R, DAVIES J, DANIELS PJ, WEINSTEIN J: Gentamicin resistance in strains of Pseudomonas acruginosa mediated by enzymatic N-acetylation of the deoxystreptamine moiety. Biochemistry (1972) 11(5):761-765.
17. DROBNIC ME, SUNE P, MONTORO JB, FERRER A, ORRIOLS R: Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. (2005) 39(1):39-44.
18. CHEER SM, WAUGH J, NOBLE S: Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs (2003) 63(22):2501-2520.
19. LERNER SA, MATZ GJ, SCHMITT BA: Prospective, randomized, blinded assessment of nephro- and ototoxicity in patients treated with gentamicin, netilmicin, and tobramycin. IAC Meeting, Congress on Chemotherapy, Washington, D.C., USA (1984).
20. GORSE GJ, BERNSTEIN JM, CRONIN RE, ETZELL PS: A comparison of netilmicin and tobramycin therapy in patients with renal impairment. Scand. J. Infect. Dis. (1992) 24(4):503-514.
21. NOONE M, POMEROY I, SAGE R, NOONE P: Prospective study of amikacin versus netilmicin in the treatment of severe infection in hospitalized patients. Am. J. Med. (1989) 86(6 Pt 2):809-813.
22. BRUMMETT RE, FOX KE: In: The Aminoglycosides, Whelton A et al. (Eds) Marcel Dekker, New York (1982):419-451.
23. LEVISON ME, MALLELA S: Increasing antimicrobial resistance: therapeutic implications for enterococcal infections. Curr. Infect. Dis. Rep. (2000) 2(5):417-423.
24. DI PERRI G, BONORA S: Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J. Antimicrob. Chemother. (2004) 54(3):593-602.
25. MILLER GH, SABATELLI FJ, NAPLES L, HARE RS, SHAW KJ: The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin-a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. J. Chemother. (1995) 7(Suppl. 2):31-44.
26. CORTOPASSI G, HUTCHIN T: A molecular and cellular hypothesis for aminoglycoside-induced deafness. Hear. Res. (1994) 78(1):27-30.
27. HUTCHIN T, HAWORTH I, HIGASHI K et al.: A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res. (1993) 21(18):4174-4179.
28. HUTCHIN TP, CORTOPASSI GA: Multiple origins of a mitochondrial mutation conferring deafness. Genetics (1997) 145(3):771-776.
29. FISCHEL-GHODSIAN N, PREZANT TR, CHALTRAW WE et al.: Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am. J. Otolaryngol. (1997) 18(3):173-178.
30. CLANCY JP, BEBOK Z, RUIZ F et al.: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. (2001) 163:1683-1692.
31. LUFT FC: Gentamicin as gene therapy. J. Mol. Med (2002) 80(9):543-544.
32. MANUVAKHOVA M, KEELING K, BEDWELL DM: Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA (2000) 6:1044-1055.
33. WILCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. (2003) 349:1433-1441.
34. HOWARD M, FRIZZELL RA, BEDWELL DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. (1996) 2:467-469.
35. BEDWELL DM, KAENJAK A, BENOS DJ et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. (1997) 3:1280-1284.
36. BARTON-DAVIS ER, CORDIER L, SHOTURMA DI, LELAND SE, SWEENEY HL: Aminoglycoside antibiotics restore dystrophin function to skeletal mucles of mdx mice. J. Clin. Invest. (1999) 104:375-381.
37. DU M, JONES JR, LANIER J et al.: Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J. Mol. Med. (2002) 80(9):595-604.
38. ROHN GN, MEYERHOFF WL, WRIGHT CG: Ototoxicity of Topical Agents. In: The Otolaryngologic Clinics of North America, Rybak L. (Ed.) WB Saunders Co., Philadelphia, PA (1993):747-758.
39. MATZ G, RYBAK L. ROLAND PS et al.: Ototoxicity of ototopical antibiotic drops in humans. Otolaryngol. Head Neck Surg. (2004) 130(3 Suppl.):S79-S82.
40. PAPP Z, REZES S, JOKAY I, SZIKLAI I: Sensorineural hearing loss in chronic otitis media. Otol. Neurotol. (2003) 24(2):141-144.
41. CUREOGLU S, SCHACHERN PA, PAPARELLA MM, LINDGREN BR. Cochlear changes in chronic otitis media. Laryngoscope (2004) 114(4):622-626.
42. FRADIS M, BRODSKY A, BEN-DAVID J et al.: Chronic otitis media treated topically with ciprofloxacin or tobramycin. Arch. Otolaryngol. Head Neck Surg. (1997) 123(10):1057-1060.
43. WAI TK, TONG MC: A benefit-risk assessment of ofloxacin otic solution in ear infection. Drug Saf. (2003) 26(6):405-420.
44. RICHARDSON GP, RUSSELL IJ: Cochlear cultures as a model system for studying aminoglycoside induced ototoxicity. Hear. Res. (1991) 53:293-311.
45. KOTECHA B, RICHARDSON GP: Ototoxicity in vitro: effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycins neamine, spermine and poly-L-Lysine. Hear. Res. (1994) 73:173-184.
46. LI L, FORGE A: Cultured explants of the vestibular sensory epithelia from adult guinea pigs and effects of gentamicin: a model for examination of hair cell loss and epithelial repair mechanisms. Aud. Neurosci. (1995) 1:111-125.
47. LÖWENHEIM H, KIL J, GÜLTIG K, ZENNER H-P: Determination of hair cell degeneration and hair cell death in neomycin treated cultures of the neonatal rat cochlea. Hear Res. (1999) 128:16-26.
48. TRAN BA HUY P, BERNARD P, SCHACHT J: Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J. Clin. Invest. (1986) 77(5):1492-1500.
49. DULON D, ZAJIC G, ARAN JM, SCHACHT J: Aminoglycoside antibiotics impair calcium entry but not viability and motility in isolated cochlear outer hair cells. J. Neurosci. Res. (1989) 24(2):338-346.
50. NOMURA K, NARUSE K, WATANABE K, SOKABE M: Aminoglycoside blockade of Ca2(+)-activated K+ channel from rat brain synaptosomal membranes incorporated into planar bilayers. J. Membr. Biol. (1990) 115(3):241-251.
51. OHMORI H: Mechano-electrical transduction currents in isolated vestibular hair cells of the chick. J. Physiol. (1985) 359:189-217.
52. KROS CJ, RUSCH A, RICHARDSON GP: Mechano-electrical transducer currents in hair cells of the cultured mouse cochlea. Proc. R. Soc. London B (1992) 249:185-193.
53. PICHLER M, WANG Z, GRABNER-WEISS C et al.: Block of P/Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics. Biochemistry (1996) 35(46):14659-14664.
54. LIN X HUME RI, NUTTALL AL: Voltage-dependent block by neomycin of the ATP-induced whole cell current of guinea-pig outer hair cells. J. Neurophysiol. (1993) 70(4):1593-1605.
55. BLANCHET C, EROSTEGUI C, SUGASAWA M, DULON D: Gentamicin blocks ACh-evoked K+ current in guinea-pig outer hair cells by impairing Ca2+ entry at the cholinergic receptor. J. Physiol. (2000) 525(Pt 3):641-654.
56. HIEL H, ERRE JP, AUROUSSEAU C et al.: Gentamicin uptake by cochlear hair cells precedes hearing impairment during chronic treatment. Audiology (1993) 32(1):78-87.
57. RICHARDSON GP, FORGE A, KROS CJ et al.: Myosin VIIA is required for aminoglycoside accumulation in cochlear hair cells. J. Neurosci. (1997) 17(24):9506-9519.
58. DE GROOT JCMJ, MEEUWESEN F, RUIZENDAAL WE, VELDMAN JE: Ultrastructural localisation of gentamicin in the cochlea. Hear. Res. (1990) 50:35-42.
59. IMAMURA S, ADAMS JC: Distribution of gentamicin in the guinea pig inner ear after local or systemic application. J. Assoc. Res. Otolaryngol. (2003) 4(2):176-195.
60. HASHINO E, SHERO M, SALVI RJ: Lysosomal augmentation during aminoglycoside uptake in cochlear hair cells. Brain Res. (2000) 887(1):90-97.
61. HASHINO E, SHERO M, SALVI RJ: Lysosomal targeting and accumulation of aminoglycoside antibiotics in sensory hair cells. Brain Res. (1997) 777(1-2):75-85.
62. DULON D, HIEL H, AUROUSSEAU C, ERRE JP, ARAN JM: Pharmacokinetics of gentamicin in the sensory hair cells of the organ of Corti: rapid uptake and long term persistence. C. R. Acad. Sci. III (1993) 316(7):682-687.
63. MARCOTTI W, VAN NETTEN SM, KROS CJ: The aminoglycoside antibiotic dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-electrical transducer channels. J. Physiol. (2005) 567(Pt 2):505-521.
64. MYRDAL SE, JOHNSON KC, STEYGER PS: Cytoplasmic and intra-nuclear binding of gentamicin does not require endocytosis. Hear. Res. (2005) 204:156-169.
65. MYRDAL SE, STEYGER PS: TRPV1 regulators mediate gentamicin penetration of cultured kidney cells. Hear. Res. (2005) 204:170-182.
66. SCHACHT J: Molecular mechanisms of drug-induced hearing loss. Hear. Res. (1986) 22:297-304.
67. WILLIAMS SE, ZENNER HP SCHACHT J: Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hear. Res. (1987) 30(1):11-18.
68. WANG BM, WEINER ND, TAKADA A, SCHACHT J: Characterization of aminoglycoside-lipid interactions and development of a refined model for ototoxicity testing. Biochem. Pharmacol. (1984) 33(20):3257-3262.
69. BARTOLAMI S, PLANCHE M, PUJOL R: Inhibition of the carbachol-evoked synthesis of inositol phosphates by ototoxic drugs in the rat cochlea. Hear. Res. (1993) 67(1-2):203-210.
70. CLERICI WJ, HENSLEY K, DIMARTINO DL, BUTTERFIELD DA. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear. Res. (1996) 98:116-124.
71. CONLON B, ARAN J, ERRE J, DW S: Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant a-lipoic acid. Hear. Res. (1999) 128:40-44.
72. GARETZ SL, ALTSCHULER RA, SCHACHT J: Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear. Res. (1994) 77(1-2):81-87.
73. SHA SH, SCHACHT J: Stimulation of free radical formation by aminoglycoside antibiotics. Hear. Res. (1999) 128(1-2):112-118.
74. SONG BB, SCHACHT J: Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hear. Res. (1996) 94(1-2):87-93.
75. HIROSE K, HOCKENBERY DM, RUBEL EW: Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hear. Res. (1997) 104(1-2):1-14.
76. PRIUSKA EM, SCHACHT J: Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem. Pharmacol. (1995) 50(11):1749-1752.
77. LESNIAK W, PECORARO VL, SCHACHT J: Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem. Res. Toxicol. (2005) 18(2):357-364.
78. CONLON BJ, PERRY BP, SMITH DW. Attenuation of neomycin ototoxicity by iron chelation. Laryngoscape (1998) 108(2):284-287.
79. SONG BB, SHA SH, SCHACHT J: Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity. Free Radic. Biol. Med. (1998) 25(2):189-195.
80. WU W-J, SHA S-H, SCHACHT J: Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol. Neurootol. (2002) 7:171-174.
81. SHEU SS, NAUDURI D, ANDERS MW: Targeting antioxidants to mitochondria: A new therapeutic direction. Biochim. Biophys. Acta (2006) 1762(2):256-265.
82. TEMPLE MD, PERRONE GG, DAWES IW. Complex cellular responses to reactive oxygen species. Trends Cell Biol. (2005) 15(6):319-326.
83. DRÖGE W: Free radicals in the physiological control of cell function. Physiol. Rev. (2002) 82:47-95.
84. JACKSON MJ, PAPA S, BOLANOS J et al.: Antioxidants, reactive oxygen and nitrogen species, gene induction and mitochondrial function. Mol. Aspects Med. (2002) 23(1-3):209-285.
85. FORGE A: Outer hair cell loss and supporting cell expansion following chronic gentamicin treatment. Hear. Res. (1985) 19:171-182.
86. FORGE A, LI L: Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hear. Res. (2000) 139(1-2):97-115.
87. LI I, NEVILL G, FORGE A. Two modes of hair cell loss from the vestibular sensory epithelia of the guinea pig inner ear. J. Comp. Neurol. (1995) 355(3):405-417.
88. JIANG H, SHA S-H, FORGE A, SCHACHT J: Caspase-independent pathways of hair cell death induced by kanamycin in vivo. Cell Death Diff. (2006) 13:20-30.
89. MATSUI JI, HAQUE A. HUSS D et al: Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo. J. Neurosci. (2003) 23(14):6111-6122.
90. MATSUI JI, OGILVIE JM, WARCHOL ME: Inhibition of caspases prevents ototoxic and ongoing hair cell death. J. Neurosci. (2002) 22(4):1218-1227.
91. CHENG AG, CUNNINGHAM LI, RUBEL EW: Hair cell death in the avian basilar papilla: characterization of the in vitro model and caspase activation. J. Assoc. Res. Otolaryngol. (2003) 4(1):91-105.
92. CUNNINGHAM LI, CHENG AG, RUBEL EW: Caspase activation in hair cells of the mouse utricle exposed to neomycin. J. Neurosci. (2002) 22(19):8532-8540.
93. FORMIGLI L, PAPUCCI L, TANI A et al.: Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J. Cel Physiol. (2000) 182(1):41-49.
94. JAATTELA M: Programmed cell death: many ways for cells to die decently. Ann. Med. (2002) 34(6):480-488.
95. MATSUI JI, GALE JE, WARCHOL ME: Critical signaling events during the aminoglycoside-induced death of sensory hair cells in vitro. J. Neurobiol. (2004) 61:250-266.
96. PIRVOLA U, XING-QUN L, VIRKKALA J et al.: Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J. Neurosci. (2000) 20(1):43-50.
97. WANG J, VAN DE WATER TR, BONNY C et al.: A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J. Neurosci. (2003) 23(24):8596-8607.
98. CUNNINGHAM LL, MATSUI JI, WARCHOL ME, RUBEL EW: Overexpression of Bcl-2 prevents neomycin-induced hair cell death and caspase-9 activation in the adult mouse utricle in vitro. J. Neurobiol. (2004) 60(1):89-100.
99. BODMER D, BRORS D, PAK K, GLODDEK B, RYAN A: Rescue of auditory hair cells from aminoglycoside toxicity by Clostridium difficile toxin B, an inhibitor of the small GTPases Rho/Rac/Cdc42. Hear. Res. (2002) 172(1-2):81-86.
100. DING D, STRACHER A, SALVI RJ: Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity, Hear. Res. (2002) 164(1-2):115-126.
101. BERTOLASO L, BINDINI D, PREVIATI M et al.: Gentamicin-induced cytotoxicity involves protein kinase C activation, glutathione extrusion and malondialdehyde production in an immortalized cell line from the organ of corti. Audiol. Neurootol. (2003) 8(1):38-48.
102. MCFADDEN SL, DING D, SALVEMINI D, SALVI RJ: M40403, a superoxide dismutase mimetic, protects cochlear hair cells from gentamicin, but not cisplatin toxicity. Toxicol. Appl. Pharmacol. (2003) 186:46-54.
103. BODMER D, BRORS D, PAK K, BODMER M, RYAN AF: Gentamicin-induced hair cell death is not dependent on the apoptosis receptor Fas. Laryngoscope (2003) 113(3):452-455.
104. KALINEC G, FERNANDEZ ZAPICO M, URRUTIA R et al.: Pivotal role of Hatakiri in the induction and prevention of gentamicin-induced hearing loss. Proc. Natl. Acad. Sci. USA (2005) 102(44):16019-16024.
105. CORBACELLA E, LANZONI I, DING D, PREVIATI M, SALVI R: Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear. Res. (2004) 197(1-2):11-18.
106. BERTOLASO I, MARTINI A, BINDINI D et al.: Apoptosis in the OC-k3 immortalized cell line treated with different agents. Audiology (2001) 40:327-335.
107. BATTAGLIA A, PAK K, BRORS D et al.: Involvement of ras activation in toxic hair cell damage of the mammalian cochlea. Neuroscience (2003) 122(4):1025-1035.
108. YLIKOSKI J, XING-QUN I, VIRKKALA J, PIRVOLA U: Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Hear. Res. (2002) 166(1-2):33-43.
109. BRUMMETT RE, FOX KE: Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob. Agents Chemother. (1989) 33(6):791-796.
110. KLIBANOV OM, FILICKO JE, DESIMONE JA, JR., TICE DS: Sensorineural hearing loss associated with intrathecal vancomycin. Ann. Pharmacother. (2003) 37(1):61-65.
111. LASH SC, WILLIAMS CP, MARSH CS et al.: Acute sixth-nerve palsy after vincristine therapy. J. Aapos. (2004) 8(1):67-68.
112. GENDEH BS, GIBB AG, AZIZ NS, KONG N, ZAHIR ZM: Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol. Head Neck Surg. (1998) 118(4):551-558.
113. BARTH RH, DEVINCENZO N: Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int. (1996) 50(3):929-936.
114. REYES MP, OSTREA EM, JR., CABINIAN AE, SCHMITT C, RINTELMANN W: Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am. J. Obstet. Gynecol. (1989) 161(4):977-981.
115. RYBAK MJ, ABATE BJ, KANG SL et al.: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. (1999) 43(7):1549-1555.
116. MINTZ U. AMIR J, PINKHAS J, DE VRIES A. Transient perceptive deafness due to erythromycin lactobionate. JAMA (1973) 225(9):1122-1123.
117. SWANSON DJ, SUNG RJ, FINE MJ et al.: Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am. J. Med. (1992) 92(1):61-68.
118. HUGUES FC, LACCOURREYE A, LASSERRE MH, TOUPET M: [Cochlear toxicity of erythromycin in elderly patients]. Therapie (1984) 39(5):591-594.
119. MCGHAN LJ, MERCHANT SN: Erythromycin ototoxicity. Otol. Neurotol. (2003) 24:701-702.
120. RESS BD, GROSS EM: Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report. Ann. Otol. Rhinol. Laryngol. (2000) 109(4):435-437.
121. SCHWEITZER VG, OLSON NR. Ototoxic effect of erythromycin therapy. Arch. Otolaryngol. (1984) 110(4):258-260.
122. LUTZ H, LENARZ T, WEIDAUER H, FEDERSPIL P, HOTH S: Ototoxicity of vancomycin: an experimental study in guinea pigs. ORL J. Otorhinolaryngol. Relat. Spec. (1991) 53:273-278.
123. BRUMMETT RE, FOX KE, JACOBS F et al.: Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch. Otolaryngol. Head Neck Surg. (1990) 116(1):61-64.
124. WOOD CA, KOHLHEPP SJ, KOHNEN PW, HOUGHTON DC, GILBERT DN: Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother. (1986) 30(1):20-24.
125. STUPP H, KUPPER K, LAGLER F, SOUS H, QUANTE M: Inner car concentrations and ototoxicity of different antibiotics in local and systemic application. Audiology (1973) 12:350-363.
126. UZUN C, KOTEN M, ADALI MK et al.: Reversible ototoxic effect of azithromycin and clarithromycin on mansiently evoked otoacoustic emissions in guinea pigs. J. Laryngol. Otol. (2001) 115(8):622-628.
127. NIELSEN-ABBRING FW, PERENBOOM RM, VAN DER HULST RJ: Quinine-induced hearing loss. ORL J. Otorhinolaryngol. Relat. Spec. (1990) 52(1):65-68.
128. TANGE RA, DRESCHLER WA, CLAESSEN FA, PERENBOOM RM: Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx (1997) 24(2):131-136.
129. PUEL J-L, BOBBIN RP, FALLON M: Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials. Otolaryngol. Head Neck Surg. (1990) 102(1):66-73.
130. KARLSSON KK, FLOCK A: Quinine causes isolated outer hair cells to change length. Neurosci. Lett. (1990) 116:101-105.
131. KARLSSON KK, ULFENDAHL M, KHANNA SM, FLOCK A: The effects of quinine on the cochlear mechanics in the isolated temporal bone preparation. Hear. Res. (1991) 53:95-100.
132. JARBOE JK, HALLWORTH R: The effect of quinine on outer hair cell shape, compliance and force. Hear. Res. (1999) 132(1-2):43-50.
133. ZHENG J, REN T, PARTHASARATHI A, NUTALL AL: Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs. Hear. Res. (2001) 154(1-2):124-134.
134. LIN X, CHEN S, TEE D: Effects of quinine on the excitability and voltage-dependent currents of isolated spiral ganglion neurons in culture. J. Neurophysiol. (1998) 79:2503-2512.
135. BOETTCHER FA, SALVI RJ: Salicylate ototoxicity: review and synthesis. Am. J. Otol. (1991) 12:33-47.
136. DAY RO, GRAHAM GG, BIERI D et al.: Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br. J. Clin. Pharmacol. (1989) 28(6):695-702.
137. HALLA JT, HARDIN JG: Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study. Ann. Rheum. Dis. (1988) 47(2):134-137.
138. BRIEN JA. Ototoxicity associated with salicylates. A brief review. Drug Saf. (1993) 9(2):143-148.
139. CHAPMAN P: Naproxen and sudden hearing loss. J. Laryngol. Otol. (1982) 96(2):163-166.
140. MCKINNON BJ, LASSEN LF: Naproxen-associated sudden sensorineural hearing loss. Mil. Med. (1998) 163(11):792-793.
141. DOUEK EE, DODSON HC, BANNISTER LH: The effects of sodium salicylate on the cochlea of guinea pigs. J. Laryngol. Otol. (1983) 93:793-799.
142. DIELER R, SHEHATA-DIELER WE, BROWNELL WE: Concomitant salicylate-induced alterations of outer hair cell subsurface cistemae and electromotility. J. Neurocytol. (1991) 20:637-653.
143. SHEHATA WE, BROWNELL WE, DIELER R: Effects of salicylate on shape, electromotility and membrane characteristics of isolated outer hair cells from guinea pig cochlea. Acta Otolaryngol. (1991) 111:707-718.
144. MCFADDEN D, PLATTSMIER HS: Aspirin abolishes spontaneous otoacoustic emissions. J. Acoust. Soc. Am. (1984) 76:443-448.
145. LONG GR, TUBIS A; Modification of spontaneous and evoked otoacoustic emissions and associated psychoacoustic microstructure by aspirin consumption. J. Acoust. Soc. Am. (1988) 84:1343-1353.
146. STEWART CE, HUDSPETH AJ: Effects of salicylates and aminoglycosides on spontaneous otoacoustic emissions in the Tokay gecko. Proc. Natl. Acad. Sci. USA (2000) 97(1):454-459.
147. HUANG ZW, LUO Y, WU Z et al.: Paradoxical enhancement of active cochlear mechanics in long-term administration of salicylate. J. Neurophysiol. (2005) 93(4):2053-2061.
148. MURUGASU E, RUSSELL IJ: Salicylate ototoxicity: The effects on basilar membrane displacement, cochlear microphonics, and neural responses in the basal turn of the guinea pig cochlea. Audit. Neurosci. (1995) 1:139-150.
149. RUSSELL I, SCHAUZ C: Salicylate ototoxicity: Effects on the stiffness and electromotility of outer hair cells isolated from the guinea pig cochlea. Aud. Neurosci. (1995) 1:309-319.
150. TUNSTALL MJ, GALE JE, ASHMORE JF: Action of salicylate on membrane capacitance of outer hair cells from the guinea pig cochlea. J. Physiol. (London) (1995) 485:739-752.
151. ZHENG J, MADISON LD, OLIVER D, FAKLER B, DALLOS P: Prestin, the motor protein of outer hair cells. Audiol. Neurootol. (2002) 7(1):9-12.
152. ZHENG J, SHEN W, HE DZ et al.: Prestin is the motor protein of cochlear outer hair cells. Nature (2000) 405(6783):149-155.
153. JASTREBOFF PJ, SASAKI CT: Salicylate-induced changes in spontaneous activity of single units in the inferior colliculus of the guinea pig. J. Acoust. Soc. Am (1986) 80:1384-1391.
154. JASTREBOFF PJ, BRENNAN JF, COLEMAN JK: Phantom auditory sensation in rats: An animal model for tinnitus. Behav. Neurosci. (1988) 102:811-822.
155. EVANS EF, BORERWE TA: Ototoxic effects of salicylates; on the responses of single cochlear nerve fibers and on cochlear potentials. Br. J. Audiol. (1982) 16:101-108.
156. STYPULKOWSKI PH: Mechanisms of salicylate ototoxicity. Hear. Res. (1990) 46:113-146.
157. CAZALS Y, HORNER KC, HUANG ZW: Alterations in average spectrum of cochleoneural actiovity by long-term salicylate treatment in the guinea pig: a plausible index of tinnitus. J. Neurophysiol. (1998) 80:2113-2120.
158. CAZALS Y: Auditory sensorineural alterations induced by salicylate. Prog. Neurobiol. (2000) 62:583-631.
159. GUITTON MJ, CASTON J, RUEL J et al.: Salicylate induces tinnitus through activation of cochlear NMDA receptors. J. Neurosci. (2003) 23(9):3944-3952.
160. PENG BG, CHEN S, LIN X: Aspirin selectively augmented M-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci. Lett. (2003) 343:21-24.
161. ARNOLD W, NADOL JB,JR., WEIDAUER H: Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics. Acta Otolaryngol. (1981) 91(5-6):399-414.
162. TUZEL IH: Comparison of adverse reactions to bumetanide and furosemide. J. Clin. Pharmacol. (1981) 21(11-12 Pt 2):615-619.
163. BATES DE, BEAUMONT SJ, BAYLIS BW. Ototoxicity induced by gentamicin and furosemide. Ann. Pharmacother. (2002) 36(3):446-451.
164. MARCUS DC: Nonsensory electrophysiology of the cochlea: Stria vascularis. In: Neurobiology of Hearing: The Cochlea, Altschuler RA et al. (Eds) Raven Press, New York (1986).
165. KOCH T, GLODDEK B: Inhibition of adenylate-cyclase-coupled G protein complex by ototoxic diuretics and cis-platinum in the inner ear of the guinea pig. Eur. Arch. Otorhinolaryngol. (1991) 248:459-464.
166. DING D, MCFADDEN SL, WOO JM, SALVI RJ: Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear. Res. (2002) 173(1-2):1-9.
167. RYBAK LP: Ototoxicity of loop diuretics. Otolaryngol. Clin. North Am. (1993) 26(5):829-844.
168. LIU JX, ZHOU XN, YUAN YG: Effects of furosemide on intracochlear oxygen tension in the guinea pig. Eur. Arch. Otorhinolaryngol. (1996) 253(6):367-370.
169. RUGGERO MA, RICH NC: Furosemide alters organ of Corti mechanics: Evidence for feedback of outer hair cells upon the basilar membrane. J. Neurosci. (1991) 11:1057-1067.
170. ALAM SA, IKEDA K, KAWASE T et al.: Acute effects of combined administration of kanamycin and furosemide on the stria vascularis studied by distortion product otoacoustic emission and transmission electron microscopy. Tohoku J. Exp. Med. (1998) 186(2):79-86.
171. KALINEC F, KACHAR B: Inhibition of outer hair cell electromotility by sulfhydryl specific reagents. Neurosci. Lett. (1993) 157:231-234.
172. KOECHEL DA. Ethacrynic Acid and Related Diuretics: relationship of structure to beneficial and detrimental actions. Ann. Rev. Pharmacol. Toxicol. (1981) 21:265-293.
173. BRUMMETT RE, BROWN RT, HIMES DL: Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid. Arch. Otolaryngol. (1979) 105(5):240-246.
174. BRUMMETT RE: Ototoxicity resulting from the combined administration of potent diuretics and other agents. Scand. Audiol. Suppl. (1981) 14(Suppl.):215-224.
175. HAYASHIDA T, HIEL H, DULON D et al.: Dynamic changes following combined treatment with gentamicin and ethacrynic acid with and without acoustic stimulation. Cellular uptake and functional correlates. Acta Otolaryngol. (1989) 108(5-6):404-413.
176. TRAN BA HUY P, MANUEL C, MEULEMANS A et al.: Ethacrynic acid facilitates gentamicin entry into endolymph of the rat. Hear. Res. (1983) 11(2):191-202.
177. CONLON BJ, MCSWAIN SD, SMITH DW: Topical gentamicin and ethacrynic acid: effects on cochlear function. Laryngoscope (1998) 108(7):1087-1089.
178. DING D, MCFADDEN SL, BROWNE RW, SALVI RJ: Late dosing with ethacrynic acid can reduce gentamicin concentration in perilymph and protect cochlear hair cells. Hear. Res. (2003) 185(1-2):90-96.
179. LIPP HP, HARTMANN JT: [Platinum compounds: metabolism, toxicity and supportive strategies]. Schweiz Rundsch Med. Prax (2005) 94(6):187-198.
180. VAN ZEIJL LG, CONIJN EA, RODENBURG M, TANGE RA, BROCAAR MP: Analysis of hearing loss due to cis-diamminedichloroplatinum-II. Arch Otorhinolaryngol. (1984) 239(3):255-262.
181. LAURELL G, JUNGNELIUS U: High-dose cisplatin treatment hearing loss and plasma concentrations. Laryngoscope (1990) 100(7):724-734.
182. VAN WARMERDAM LJ, RODENHUIS S, VAN DER WALL E, MAES RA, BEIJNEN JH: Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br. J. Cancer (1996) 73(8):979-984.
183. MCALPINE D, JOHNSTONE BM: The ototoxic mechanism of cisplatin. Hear. Res. (1990) 47(3):191-203.
184. HINOJOSA R, RIGGS LC, STRAUSS M, MATZ GJ: Temporal bone histopathology of cisplatin ototoxicity. Am. J. Otol. (1995) 16(6):731-740.
185. GARETZ SL, SCHACHT J: Ototoxicity: Of mice and men. In: Clinical Aspects of Hearing, Van de Water TR et al. (Eds) Springer, New York (1996):116-154.
186. RYBAK L, HUSAIN K, EVENSON L et al.: Protection by 4-methylthiobenzoic acid agains cisplatin-induced ototoxicity: antioxidant system. Pharmacol. Toxicol. (1997) 81:173-179.
187. RYBAK L, WHITWORTH C, SOMANI S: Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope (1999) 109:1740-1744.
188. RYBAK LP, HUSAIN K, MORRIS C, WHITWORTH C, SOMANI S: Effect of protective agents against cisplatin ototoxicity. Am. J. Otol. (2000) 21(4):513-520.
189. RYBAK LP, HUSAIN K, WHITWORTH C, SOMANI SM: Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol. Sci. (1999) 47(2):195-202.
190. RYBAK LP, SOMANI S: Ototoxicity. Amelioration by protective agents. Ann. NY Acad. Sci. (1999) 884:143-151.
191. DING D, LANZONI I, CORBACELLI E et al.: PD98059 protects cochlear hair cells from cisplatin. 28th ARO Midwinter Meeting, New Orleans, LA, USA (2005).
192. DEVARAJAN P, SAVOCA M, PARK M-S et al.: Cisplatin-induced apoptosis of auditory cells: Role of death receptor and mitochondrial pathways. Hear.Res. (2002) 174:45-54.
193. SO HS, PARK C, KIM HJ et al.: Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear. Res. (2005) 204(1-2):127-139.
194. KALINEC GM, WEBSTER P, LIM DJ, KALINEC F: A cochlear cell fine as an in vitro system for drug ototoxicity screening. Audiol. Neurootol. (2003) 8:177-189.
195. KOPKE RD, LIU W, GABAIZADEH R et al.: Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. (1997) 18(5):559-571.
196. WAKE M, TAKENO S, IBRAHIM D, HARRISON R, MOUNT R. Carboplatin ototoxicity: an animal model. J. Laryngol. Otol. (1993) 107(7):585-589.
197. TAKENO S, HARRISON RV, IBRAHIM D, WAKE M, MOUNT RJ: Cochlear function after selective inner hair cell degeneration induced by carboplarin. Hear. Res. (1994) 75(1-2):93-102.
198. TAKENO S, HARRISON RV, MOUNT RJ, WAKE M, HARADA Y: Induction of
199. BAUER CA, BROZOSKI TJ: Cochlear structure and function after round window application of ototoxins. Hear. Res. (2005) 201(1-2):121-131.
200. MOUNT RJ, TAKENO S, WAKE M, HARRISON RV: Carboplatin ototoxicity in the chinchilla: lesions of the vestibular sensory epithelium. Acta Otolaryngol. Suppl. (1995) 519:60-65.
201. TAKENO S, WAKE M, MOUNT RJ, HARRISON RV: Degeneration of spiral ganglion cells in the chinchilla after inner hair cell loss induced by carboplatin. Audiol. Neurootol. (1998) 3(5):281-290.
202. WAKE M, ANDERSON J, TAKENO S, MOUNT RJ, HARRISON RV: Otoacoustic emission amplification after inner hair cell damage. Acta Otolaryngol. (1996) 116(3):374-381.
203. WAKE M, TAKENO S, MOUNT RJ, HARRISON RV: Recording from the inferior colliculus following cochlear inner hair cell damage. Acta Otolaryngol. (1996) 116(5):714-720.
204. HUSAIN K, WHITWORTH C, SOMANI SM, RYBAK LP: Carboplatin-induced oxidative stress in rat cochlea. Hear. Res. (2001) 159(1-2):14-22.
205. HENDERSON D, HU BH, MCFADDEN SL, ZHENG XY, DING D: The role of glutathione in carboplatin ototoxicity in the chinchilla. Noise Health (2000) 3(9):1-10.
206. DING DL, WANG J, SALVI R et al.: Selective loss ofinncr hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann. NY Acad. Sci. (1999) 884:152-170.
207. HU BH, MCFADDEN SL, SALVI RJ, HENDERSON D: Intracochlear infusion of buthionine sulfoximine potentiates carboplatin ototoxicity in the chinchilla. Hear. Res. (1999) 128(1-2):125-134.
208. LOCKWOOD DS, DING DL, WANG J, SALVI RJ: D-Methionine attenuates inner hair cell loss in carboplatin-treated chinchillas. Audiol. Neurootol. (2000) 5(5):263-266.
209. HUSAIN K. WHITWORTH C, SOMANI SM, RYBAK LP: Partial protection by lipoic acid against carboplantin-induced ototoxicity in rats. Biomed. Environ. Sci. (2005) 18(3):198-206.
210. MULDOON LL, PAGEL MA, KROLL RA et al.: Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Cancer Res. (2000) 6(1):309-315.
211. HUSAIN K, WHITWORTH C, HAZELRIGG S, RYBAK L: Carboplatin-induced oxidative injury in rat inferior colliculus. Int. J. Toxicol. (2003) 22(5):335-342.
212. RYBAK L: Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus. Int. Tinnitus J. (2005) 11(1):23-30.
213. MCCRACKEN GH, Jr: Aminoglycoside toxicity in infants and children. Am. J. Med (1986) 80(6B):172-178.
214. BORRADORI C, FAWER CL, BUCLIN T, CALAME A. Risk factors of sensorineural hearing loss in preterm infants. Biol. Neonate (1997) 71(1):1-10.
215. RAKOVER Y, KEYWAN K, ROSEN G: Safety of topical ear drops containing ototoxic antibiotics. J. Otolaryngol. (1997) 26(3):194-196.
216. SKINNER R, PEARSON AD, AMINEDDINE HA, MATHIAS DB, CRAFT AW: Orotoxicity of cisplatinum in children and adolescents. Br. J. Cancer (1990) 61(6):927-931.
217. KNIGHT KR, KRAEMER DF, NEUWELT EA: Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. (2005) 23(34):8588-8596.
218. RADEMAKER-LAKHAI JM, CRUL M, ZUUR L et al.: Relationship between cisplatin administration and the development of ototoxicity. J. Clin. Oncol. (2006) 24(6):918-924.
219. GORDON JS, PHILLIPS DS, HELT WJ, KONRAD-MARTIN D, FAUSTI SA: Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. J. Rehabil Res. Dev. (2005) 42(3):353-361.
220. LONSBURY-MARTIN BL, MARTIN GK, MVCCOY MJ, WHITEHEAD ML: New approaches to the evaluation of the auditory system and a current analysis of otoacoustic emissions. Otolaryngol. Head Neck Surg. (1995) 112(1):50-63.
221. BHANSALI SA, HONRUBIA V: Current status of electronystagmography testing. Otolaryngol. Head Neck Surg. (1999) 120(3):419-426.
222. ALI MZ, GOETZ MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. (1997) 24(5):796-809.
223. CONTOPOULOS-IOANNIDIS DG, GIOTIS ND, BALIATSA DV, IOANNIDIS JP: Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics (2004) 114(1):e111-e118.
224. BLACK FO, PESZNECKER S, STALLINGS V: Permanent gentamicin vestibulotoxicity. Otol. Neurotol. (2004) 25(4):559-569.
225. LIM DJ: Functional structure of the organ of Corti: a review. Hear. Res. (1986) 22:117-146.